Overcoming Hurdles in Emerging Therapy Development
The development of emerging therapies poses unique manufacturing and formulation challenges for drug developers as candidates like cell and gene therapies advance through the pipeline.
As precision medicines garner increasing attention, drug makers have intensified their efforts to bring emerging therapies such as cell and gene therapies to market. This article gives an overview of cell/gene therapies in the making and explores the challenges biomanufacturers face in developing and manufacturing such inherently complex molecules. Unlike traditional small-molecule drugs and conventional antibody-based biologics, the roadblocks to developing and manufacturing cell and gene therapies can get complicated because of their molecular complexity and the fact that their mechanisms of action are not fully understood.
Download the
BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook.
Article Details
BioPharm International eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 4-9
Citation
When referring to this article, please cite it as F. Mirasol, "Overcoming Hurdles in Emerging Therapy Development, " BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
